Tag: astellas

MD Anderson, Astellas Pharma sign option agreement for monoclonal antibody drug targeting acute myeloid leukemia

| April 3, 2015 | 0 Comments

( University of Texas M. D. Anderson Cancer Center ) The University of Texas MD Anderson Cancer Center and Astellas Pharma Inc.

Continue Reading

MD Anderson, Astellas Pharma Sign Option Agreement

| April 3, 2015 | 0 Comments

The University of Texas MD Anderson Cancer Center and Astellas Pharma Inc.

Continue Reading

U.S. FDA Approves New Indication for the Use of XTANDI(R) (Enzalutamide) Capsules for Patients With Metastatic …

| September 10, 2014 | 0 Comments

Medivation, Inc. and Astellas Pharma Inc. announced today that the U.S.

Continue Reading

Prostate Cancer Research Receives a Boost

| September 3, 2014 | 0 Comments

First Recipients of the CUA-CUOG Astellas Research Grant Program Announced  MARKHAM, ON , Sept. 3, 2014 /CNW/ – The Canadian Urologic Oncology Group (CUOG), Canadian Urological Association (CUA) and Astellas …

Continue Reading

Cancer Research UK and Cancer Research Technology Join Forces with Astellas on Autophagy to Find New Cancer Treatments

| August 8, 2014 | 0 Comments

TOKYO, Aug. 8, 2014 /PRNewswire/ — Cancer Research UK and its commercial arm, Cancer Research Technology (“CRT”), are to join forces with Astellas Pharma Inc. (Tokyo, President & CEO: Yoshihiko Hatanaka, “Astellas”) to find new drug targets in the fight against cancer, with an initial focus on pancreatic cancer.

Continue Reading

XTANDI™ (Enzalutamide) Authorized in the European Union for Advanced Prostate Cancer

| June 24, 2013 | 0 Comments

CHERTSEY, England & SAN FRANCISCO–(BUSINESSWIRE)– Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. (Nasdaq: MDVN) announced …

Continue Reading

XTANDI™▼ (Enzalutamide) Authorised in the European Union (EU) for Advanced Prostate Cancer

| June 24, 2013 | 0 Comments

Today, Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. , and Medivation, Inc

Continue Reading

Aveo slumps as Astellas pares cancer drug support

| May 24, 2013 | 0 Comments

Shares of Aveo Oncology sank Friday after the company said its partner Astellas won't ask European Union regulators to approve their kidney cancer pill tivozanib.

Continue Reading